Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07235319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

StatusRecruiting
PhasePhase 3
Started2026-04-16
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Nov 20, 2031 → Apr 16, 2032
See other at-risk trials from Sun Yat-sen University

Amendment history

2026-08-26
Study Status, Sponsor/Collaborators, Contacts/Locations v1
Primary completion pushed: 2031-11-20 → 2032-04-16
Completion pushed: 2034-11-20 → 2035-04-16
Start dateestimated 2025-11-20→confirmed 2026-04-16
Study sitesdetails revised at 2 of 5 sites
2025-11-17
Original filing
This phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. The study aims to evaluate whether salvage locoregional radiotherapy is non-inferior to immediate radiotherapy following PD-1 inhibitor plus GP in de novo metastatic NPC, with potential for reduced toxicity.
Trial Details
NCT Number NCT07235319
Lead Sponsor Sun Yat-sen University
Conditions Nasopharangeal Cancer, Distant Metastasis
Enrollment 260 participants
Start Date 2026-04-16
Primary Completion 2032-04-16 (estimated)
Study Completion 2035-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-28